184 related articles for article (PubMed ID: 32557810)
41. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
Verstovsek S; Komatsu N; Gill H; Jin J; Lee SE; Hou HA; Sato T; Qin A; Urbanski R; Shih W; Zagrijtschuk O; Zimmerman C; Mesa RA
Future Oncol; 2022 Sep; 18(27):2999-3009. PubMed ID: 35924546
[TBL] [Abstract][Full Text] [Related]
42. Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.
Buxhofer-Ausch V; Steurer M; Sormann S; Schloegl E; Schimetta W; Gisslinger B; Ruckser R; Gastl G; Gisslinger H
Eur J Haematol; 2016 Dec; 97(6):511-516. PubMed ID: 27037858
[TBL] [Abstract][Full Text] [Related]
43. Current treatment practice for essential thrombocythaemia in adults.
Griesshammer M; Bangerter M; Grünewald M
Expert Opin Pharmacother; 2001 Mar; 2(3):385-93. PubMed ID: 11336593
[TBL] [Abstract][Full Text] [Related]
44. [Anagrelide in primary thrombocythemia].
Knutsen H; Hysing J
Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
[TBL] [Abstract][Full Text] [Related]
45. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
46. Anagrelide: 20 years later.
Emadi A; Spivak JL
Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
[TBL] [Abstract][Full Text] [Related]
47. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
Barbui T; Finazzi G
Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
[TBL] [Abstract][Full Text] [Related]
48. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Finazzi G; Ruggeri M; Rodeghiero F; Barbui T
Br J Haematol; 2000 Sep; 110(3):577-83. PubMed ID: 10997967
[TBL] [Abstract][Full Text] [Related]
49. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Randi ML; Rossi C; Fabris F; Girolami A
Clin Appl Thromb Hemost; 2000 Jan; 6(1):31-5. PubMed ID: 10726046
[TBL] [Abstract][Full Text] [Related]
50. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Elliott MA; Tefferi A
Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
[TBL] [Abstract][Full Text] [Related]
51. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
Petrides PE
Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
[TBL] [Abstract][Full Text] [Related]
52. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
53. Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study.
Stuckey R; Ianotto JC; Santoro M; Czyż A; Perez Encinas MM; Gómez-Casares MT; Noya Pereira MS; de Nałęcz AK; Gołos A; Lewandowski K; Szukalski Ł; González-Martín JM; Wróbel T; Sobas MA
Br J Haematol; 2022 Oct; 199(1):86-94. PubMed ID: 35906782
[TBL] [Abstract][Full Text] [Related]
54. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Barbui T
Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
[TBL] [Abstract][Full Text] [Related]
55. Management of patients with essential thrombocythemia: current concepts and perspectives.
Briere J; Guilmin F
Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
[TBL] [Abstract][Full Text] [Related]
56. Long-term management of thrombocytosis in essential thrombocythaemia.
Birgegård G
Ann Hematol; 2009 Jan; 88(1):1-10. PubMed ID: 18629498
[TBL] [Abstract][Full Text] [Related]
57. Update on diagnosis and management of essential thrombocythemia.
Gisslinger H
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):430-6. PubMed ID: 16810619
[TBL] [Abstract][Full Text] [Related]
58. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
Ito T; Hashimoto Y; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982
[TBL] [Abstract][Full Text] [Related]
60. The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.
Treliński J; Tybura M; Smolewski P; Robak T; Chojnowski K
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):646-51. PubMed ID: 19741509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
